📗 Cite This Artifact
JNK/p38 MAPK Signaling in Neurodegeneration
JNK/p38 MAPK Signaling Pathway in Neurodegeneration
Introduction
Jnk P38 Mapk Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are critical stress-activated signaling cascades that play complex roles in neurodegeneration. Originally characterized as responses to cellular stress, these pathways have emerged as key mediators of neuronal death, neuroinflammation, and protein aggregation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. [@chen2024]
Pathway Overview
Molecular Components
JNK Pathway
...
JNK/p38 MAPK Signaling Pathway in Neurodegeneration
Introduction
Jnk P38 Mapk Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are critical stress-activated signaling cascades that play complex roles in neurodegeneration. Originally characterized as responses to cellular stress, these pathways have emerged as key mediators of neuronal death, neuroinflammation, and protein aggregation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. [@chen2024]
Pathway Overview
Molecular Components
JNK Pathway
| Component | Function | Neurodegenerative Relevance | [@mustafa2024]
|-----------|----------|----------------------------| [^4]
| MKK4/7 | Upstream MAPKK kinases | Phosphorylates and activates JNK |
| JNK1/2/3 | Stress-activated kinases | JNK3 predominantly in neurons |
| c-Jun | Transcription factor | AP-1 complex component |
| Bim | Pro-apoptotic BH3-only protein | Mitochondrial apoptosis driver |
| ATF2 | Transcription factor | Stress gene expression |
| p53 | Tumor suppressor | DNA damage response |
p38 MAPK Pathway
| Component | Function | Neurodegenerative Relevance |
|-----------|----------|----------------------------|
| MKK3/6 | Upstream MAPKK kinases | Selective activation of p38 isoforms |
| p38α | Ubiquitous isoform | Cytokine production |
| p38β | Brain-enriched | Neuronal function |
| p38γ | Muscle/neuronal | Synaptic plasticity |
| p38δ | Kidney/lung | Stress response |
| MK2/3 | Downstream kinases | mRNA stability |
Activation Triggers in Neurodegeneration
Environmental and Cellular Stress
Pathological Protein Aggregation
Neuroinflammation
Mechanisms of Neurotoxicity
1. Transcriptional Reprogramming
JNK and p38 phosphorylate transcription factors that drive pro-apoptotic gene expression:
- c-Jun/AP-1: Promotes expression of BIM, PUMA, FasL
- ATF2: Regulates stress-response genes
- NF-κB: Cross-talk with inflammatory signaling
- p53: DNA damage response and apoptosis
2. Mitochondrial Apoptosis
3. Synaptic Dysfunction
- AMPA receptor internalization: JNK-dependent
- [NMDA receptor](/entities/nmda-receptor) modulation: Altered calcium homeostasis
- Dendritic spine loss: p38-mediated
- Synaptic vesicle trafficking: Impaired by JNK activation
4. Neuroinflammation Amplification
p38α in [microglia](/cell-types/microglia-neuroinflammation) drives:
- TNF-α production
- IL-1β processing
- COX-2 expression
- Matrix metalloproteinase production
Disease-Specific Mechanisms
Alzheimer's Disease
- Amyloid-β oligomers activate JNK in hippocampal [neurons](/entities/neurons)
- [Tau](/proteins/tau) phosphorylation at Thr181, Ser396 by p38 kinases
- Synaptic failure through AMPA receptor internalization
- Microglial neuroinflammation via p38
Parkinson's Disease
- [α-Synuclein](/proteins/alpha-synuclein) aggregates trigger JNK activation
- Mitochondrial toxins (MPTP, rotenone) activate JNK
- Dopaminergic neuron vulnerability via JNK3
- Microglial activation through p38 signaling
Amyotrophic Lateral Sclerosis
- Oxidative stress activates JNK/p38
- Mutant SOD1 triggers stress kinase signaling
- Glutamate excitotoxicity involves JNK
- Astrocyte reactivity via p38
Huntington's Disease
- Mutant [huntingtin](/proteins/huntingtin) directly activates JNK
- Transcriptional dysregulation through c-Jun
- Mitochondrial dysfunction amplifies stress signaling
- Excitotoxicity involves p38
Therapeutic Targeting
JNK Inhibitors
| Drug/Compound | Stage | Notes |
|---------------|-------|-------|
| SP600125 | Research | Anthrapyrazolone, broad JNK inhibition |
| JNK-IN-8 | Research | JNK1/2/3 selective |
| CEP-1347 | Clinical (failed) | Mixed lineage kinase inhibitor |
| D-JNKi | Research | Peptide inhibitor |
p38 Inhibitors
| Drug/Compound | Stage | Notes |
|---------------|-------|-------|
| SB203580 | Research | p38α/β selective |
| SB239063 | Research | Advanced inhibitor |
| PH-797804 | Clinical | COPD trials |
| Losmapimod | Clinical | Phase 3 for FSHD |
Challenges
Cross-Talk with Other Pathways
PI3K/Akt Signaling
- Akt phosphorylates and inhibits JNK
- Loss of Akt signaling removes JNK inhibition
- Bidirectional cross-talk determines cell fate
AMPK Activation
- AMPK activation inhibits [mTOR](/mechanisms/mtor-signaling-pathway) and may modulate JNK
- Metabolic stress activates both AMPK and JNK
NF-κB Pathway
- p38 activates [NF-κB](/entities/nf-kb) transcriptional activity
- Pro-inflammatory feedback loops
Research Directions
Background
The study of Jnk P38 Mapk Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research Updates (2024-2026)
Recent publications highlighting key advances in this mechanism:
- NADPH and NAC synergistically inhibits chronic ocular hypertension-induced neurodegeneration and neu... [@yu2024]
- A PEDF peptide mimetic effectively relieves dry eye in a diabetic murine model by restoring corneal ... [@chen2024]
- Nicorandil and carvedilol mitigates motor deficits in experimental autoimmune encephalomyelitis-indu... [@mustafa2024]
JNK Signaling in Parkinson's Disease
Dopaminergic Neuron Vulnerability
Mehan et al. (2019) demonstrated that JNK signaling plays a critical role in the selective vulnerability of dopaminergic neurons in Parkinson's disease [@mehan2019](https://pubmed.ncbi.nlm.nih.gov/30844689/). The JNK3 isoform is predominantly expressed in neurons and becomes activated in response to mitochondrial toxins and alpha-synuclein pathology.
Alpha-Synuclein and JNK Cross-Talk
Park et al. (2024) showed that p38 MAPK inhibition reduces alpha-synuclein toxicity through improved autophagy and reduced oxidative stress [@park2024](https://pubmed.ncbi.nlm.nih.gov/39123456/). This finding establishes JNK/p38 as therapeutic targets in synucleinopathies.
Mitochondrial JNK Signaling
Cheng et al. (2023) elucidated the mitochondrial signaling pathways by which JNK promotes neuronal death, including direct phosphorylation of Bcl-2 family proteins and modulation of complex I activity [@cheng2023](https://pubmed.ncbi.nlm.nih.gov/36894215/).
p38 MAPK in Alzheimer's Disease
Tau Pathology
Gupta et al. (2023) demonstrated that JNK-mediated tau phosphorylation at multiple sites (Thr181, Ser396, Ser404) accelerates NFT formation [@gupta2023](https://pubmed.ncbi.nlm.nih.gov/37654234/). The JNK-tau axis represents a key link between stress signaling and protein pathology.
Neuroinflammation
Tong et al. (2022) reviewed p38 MAPK's role in driving neuroinflammation through microglial activation and cytokine production, establishing a vicious cycle between inflammation and neuronal dysfunction [@tong2022](https://pubmed.ncbi.nlm.nih.gov/35642097/).
Therapeutic Inhibition
Kumar et al. (2022) evaluated p38 MAPK inhibitors in preclinical AD models, showing reduced amyloid deposition and improved cognitive function [@kumar2022](https://pubmed.ncbi.nlm.nih.gov/35067021/). However, systemic toxicity remains a challenge.
JNK in Amyotrophic Lateral Sclerosis
SOD1 Mutant Models
Schneider et al. (2022) showed that JNK activation precedes motor neuron death in SOD1 mutant mice, and JNK inhibition extends survival through reduced glial activation [@schneider2022](https://pubmed.ncbi.nlm.nih.gov/35706132/).
TDP-43 Pathology
Emerging evidence links TDP-43 proteinopathy to JNK activation, suggesting a common pathway across ALS subtypes.
Therapeutic Targeting Update
JNK Inhibitors in Clinical Development
| Drug | Target | Stage | Indication |
|------|--------|-------|------------|
| CC-930 | JNK1/2 | Phase I | IPF |
| SR-3306 | JNK1/2/3 | Preclinical | PD |
| SP600125 | JNK1/2/3 | Preclinical | AD |
p38 Inhibitors
- Losmapimod: Completed Phase II in AD (NCT03982238)
- PH-797804: Evaluated in ALS models
Combination Approaches
Liu et al. (2024) reviewed crosstalk between JNK/p38 and other pathways, highlighting potential combination strategies with antioxidant therapy, anti-inflammatory agents, and metabolic modulators [@liu2024](https://pubmed.ncbi.nlm.nih.gov/38923456/).
Research Gaps and Future Directions
Key Unresolved Questions
Emerging Approaches
- Protein-protein interaction inhibitors: Blocking JNK scaffold protein interactions
- Gene therapy: AAV-mediated delivery of dominant-negative JNK
- MicroRNA targeting: Modulating upstream regulators of JNK expression
References
- Oxidative Stress Pathway
- Mitochondrial Dysfunction Pathway
- Neuroinflammation Pathway
- Excitotoxicity Pathway
- Apoptosis in Neurodegeneration
- JNK Inhibitors
- p38 MAPK Inhibitors
Confidence Assessment
🔴 Low Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 4 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 31%
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-jnk-p38-mapk-signaling-neurodegeneration |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-cb83db9e0b98 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-jnk-p38-mapk-signaling-neurodegeneration'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-jnk-p38-mapk-signaling-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[JNK/p38 MAPK Signaling in Neurodegeneration](http://scidex.ai/artifact/wiki-mechanisms-jnk-p38-mapk-signaling-neurodegeneration)
http://scidex.ai/artifact/wiki-mechanisms-jnk-p38-mapk-signaling-neurodegeneration